- Associated Press•5 hours ago
The South San Francisco, California-based company said it had net income of 74 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- GlobeNewswire•7 hours ago
Omecamtiv Mecarbil Advancing to Phase 3 With Agreement from FDA on Key Elements of Special Protocol Assessment. VIGOR-ALS Enrolling Patients with ALS Who Have Completed VITALITY-ALS. $65 Million Recently ...
- GlobeNewswire•10 days agoCytokinetics Announces First Patient Enrolled in VIGOR-ALS, an Open-Label Extension Clinical Trial of Tirasemtiv
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016-- Cytokinetics, Inc. today announced the first patient has been enrolled in VIGOR-ALS, an open-label extension clinical trial designed to assess the long-term ...
Cytokinetics, Incorporated (CYTK)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||9.51 x 300|
|Ask||10.15 x 500|
|Day's Range||8.77 - 9.02|
|52wk Range||6.00 - 13.18|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.23|
|Avg Vol (3m)||352,036|
|Dividend & Yield||N/A (N/A)|